{"id":"menc","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Injection site pain","drugRate":"20%","severity":"Mild"},{"effect":"Redness at injection site","drugRate":"15%","severity":"Mild"},{"effect":"Swelling at injection site","drugRate":"10%","severity":"Mild"},{"effect":"Fever (≥38°C)","drugRate":"10%","severity":"Mild"}],"contraindications":["Hypersensitivity to any component of the vaccine"],"specialPopulations":{"Geriatric":"Efficacy and safety in adults over 65 years of age have not been fully evaluated.","Lactation":"Safety in lactating women has not been established.","Pediatric":"Safe and effective in children over 2 years of age.","Pregnancy":"Not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus."}},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2000-01-01","type":"Approval","milestone":"First approval outside the US","regulator":"EMA"}],"_dailymed":{"setId":"2dc730d5-55fd-4e98-8c8a-daa7d8f872b0","title":"MENVEO (MENINGOCOCCAL (GROUPS A, C, Y AND W-135) OLIGOSACCHARIDE DIPHTHERIA CRM197 CONJUGATE VACCINE) KIT MENVEO (MENINGOCOCCAL (GROUPS A, C, Y AND W-135) OLIGOSACCHARIDE DIPHTHERIA CRM197 CONJUGATE VACCINE) INJECTION, SOLUTION [GLAXOSMITHKLINE BIOLOGICALS SA]"},"aiSummary":"MenC, developed by Novartis Vaccines, is a vaccine designed to prevent meningococcal disease caused by Neisseria meningitidis serogroup C. The vaccine works by stimulating the immune system to produce antibodies against the bacterial capsular polysaccharide. Despite its efficacy, MenC does not have an FDA label, indicating it may be approved in other regions or used under specific circumstances. Common side effects include injection site reactions and mild fever. The vaccine is generally well-tolerated, but contraindications and precautions should be considered before administration.","ecosystem":[],"mechanism":{"target":"Capsular polysaccharide of Neisseria meningitidis serogroup C","novelty":"MenC was one of the earlier conjugate vaccines developed to improve the immune response in young children.","modality":"Active immunization","drugClass":"Conjugate vaccine","explanation":"The vaccine contains purified capsular polysaccharide from Neisseria meningitidis serogroup C, which acts as an antigen to elicit an immune response.","oneSentence":"MenC stimulates the immune system to produce antibodies against the capsular polysaccharide of Neisseria meningitidis serogroup C.","technicalDetail":"Upon vaccination, the capsular polysaccharide is recognized by B cells, leading to the production of specific antibodies that can neutralize the bacteria and prevent infection."},"_scrapedAt":"2026-03-28T00:49:52.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"N/A","launchDate":"N/A","annualCostUS":"N/A","currentRevenue":"N/A","patientPopulation":"Children and adults at risk of meningococcal disease","peakSalesEstimate":"N/A"},"references":[],"biosimilars":[],"competitors":["Menactra (Sanofi Pasteur)","Menveo (GlaxoSmithKline)"],"indications":{"approved":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT02955797","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-24","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":918},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT00352963","phase":"PHASE3","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-30","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":480},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT00674583","phase":"PHASE3","title":"Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-09","conditions":"Infections, Meningococcal","enrollment":414},{"nctId":"NCT02639351","phase":"PHASE1","title":"Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-01","conditions":"Infections, Meningococcal","enrollment":80},{"nctId":"NCT00503165","phase":"PHASE4","title":"A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix","status":"COMPLETED","sponsor":"Public Health England","startDate":"2007-07","conditions":"Vaccination","enrollment":30},{"nctId":"NCT03838588","phase":"","title":"The Tracking Molecular Evolution for NSCLC (T-MENC) Study","status":"UNKNOWN","sponsor":"Geneplus-Beijing Co. Ltd.","startDate":"2018-11-06","conditions":"Lung Neoplasms, Lung Cancer, Nonsmall Cell Lung Cancer","enrollment":200},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT00586612","phase":"PHASE3","title":"Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":313},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00326118","phase":"PHASE3","title":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":433},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT01345721","phase":"PHASE3","title":"Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Meningococcal Disease","enrollment":205},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT00657709","phase":"PHASE3","title":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Serogroup B Meningococcal Meningitis","enrollment":3630},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT01434680","phase":"PHASE2","title":"Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-09","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":992},{"nctId":"NCT00334334","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Infections, Streptococcal","enrollment":1572},{"nctId":"NCT00322335","phase":"PHASE3","title":"Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":230},{"nctId":"NCT00327184","phase":"PHASE3","title":"Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":709},{"nctId":"NCT00263653","phase":"PHASE3","title":"Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":297},{"nctId":"NCT00258700","phase":"PHASE3","title":"Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":478},{"nctId":"NCT00323050","phase":"PHASE3","title":"Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":468},{"nctId":"NCT00135486","phase":"PHASE2","title":"Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-03","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT00135564","phase":"PHASE2","title":"Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT01359449","phase":"PHASE3","title":"Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-05","conditions":"Meningitis, Meningococcal Infection","enrollment":123},{"nctId":"NCT01339923","phase":"PHASE3","title":"A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1409},{"nctId":"NCT01459432","phase":"","title":"Understanding Immunity Persistence After Adolescent MenC Vaccination","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-11","conditions":"Antibody Persistance After Booster Dose of Men C Vaccine","enrollment":134},{"nctId":"NCT01129518","phase":"PHASE4","title":"Can we Reduce the Number of Vaccine Injections for Children?","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-06","conditions":"Invasive Meningococcal Disease","enrollment":404},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT00617760","phase":"PHASE3","title":"Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)","enrollment":330},{"nctId":"NCT00310687","phase":"PHASE4","title":"Persistence of Immune Response After Vaccination With MCC","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Prevention of Meningococcal Infection","enrollment":1244},{"nctId":"NCT00667602","phase":"PHASE3","title":"Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Meningitis","enrollment":662},{"nctId":"NCT00392808","phase":"PHASE4","title":"Immunogenicity of the Booster Dose of Two MenC Vaccines","status":"COMPLETED","sponsor":"Centro Superior de Investigación en Salud Publica","startDate":"2007-01","conditions":"Meningococcal Infection","enrollment":389},{"nctId":"NCT01126996","phase":"","title":"Understanding the Persistence of Immunity After MenC Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-06","conditions":"Healthy","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":464,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"MenC","genericName":"MenC","companyName":"Novartis Vaccines","companyId":"novartis-vaccines","modality":"Biologic","firstApprovalDate":"N/A","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}